A phase II trial using etanercept, a recombinant tumour necrosis factor antagonist, in metastatic breast cancer
Förster, Adrian L. Harris(University of Oxford), Trivadi S. Ganesan(Churchill Hospital), Frances R. Balkwill(Queen Mary University of London), Kanchan Kaur(Churchill Hospital), Susan Hoare(Queen Mary University of London), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Denis Talbot(Royal Adelaide Hospital), Jeremy Braybrooke(University Hospitals Bristol NHS Foundation Trust)
UCL Discovery (University College London)
January 1, 2002
Cited by 1
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k